A

t first glance, the landmark experiments using CRISPR to correct a mutation in human embryos represent a breakthrough, since they demonstrated three key things: that CRISPR can delete the gene it’s supposed to in a viable embryo, that it can make the change in a way that causes all of an embryo’s cells to have it (when some embryo cells but not others have their DNA changed it’s called mosaicism and would be a problem), and that CRISPR can do this with few if any unintended edits, or off-target effects.

But when STAT spoke to the lead scientist, reproductive biologist Shoukhrat Mitalipov of Oregon Health and Science University, two days before his study was published in Nature, he had a different view on his experiment.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy